172 related articles for article (PubMed ID: 35455421)
1. A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile.
Xu W; Cong Z; Duan Q; Wang Q; Su S; Wang R; Lu L; Xue J; Jiang S
Pharmaceuticals (Basel); 2022 Mar; 15(4):. PubMed ID: 35455421
[TBL] [Abstract][Full Text] [Related]
2. A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.
Pan C; Cai L; Lu H; Lu L; Jiang S
J Biol Chem; 2011 Aug; 286(32):28425-34. PubMed ID: 21690094
[TBL] [Abstract][Full Text] [Related]
3. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Pan C; Cai L; Lu H; Qi Z; Jiang S
J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy.
Li W; Yu F; Wang Q; Qi Q; Su S; Xie L; Lu L; Jiang S
AIDS; 2016 Mar; 30(6):827-38. PubMed ID: 26595538
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
[TBL] [Abstract][Full Text] [Related]
6. Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).
Zhang D; Li W; Jiang S
Expert Opin Ther Pat; 2015 Feb; 25(2):159-73. PubMed ID: 25428639
[TBL] [Abstract][Full Text] [Related]
7. Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.
Cai L; Pan C; Xu L; Shui Y; Liu K; Jiang S
FASEB J; 2012 Mar; 26(3):1018-26. PubMed ID: 22085645
[TBL] [Abstract][Full Text] [Related]
8. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
9. Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action.
Wang C; Cheng S; Zhang Y; Ding Y; Chong H; Xing H; Jiang S; Li X; Ma L
Viruses; 2019 Sep; 11(9):. PubMed ID: 31480738
[TBL] [Abstract][Full Text] [Related]
10. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
11. IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies.
Bi W; Xu W; Cheng L; Xue J; Wang Q; Yu F; Xia S; Wang Q; Li G; Qin C; Lu L; Su L; Jiang S
PLoS Pathog; 2019 Dec; 15(12):e1008082. PubMed ID: 31805154
[TBL] [Abstract][Full Text] [Related]
12. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
13. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
[TBL] [Abstract][Full Text] [Related]
14. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.
Lu L; Pan C; Li Y; Lu H; He W; Jiang S
Retrovirology; 2012 Dec; 9():104. PubMed ID: 23217195
[TBL] [Abstract][Full Text] [Related]
15. Enfuvirtide-PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties.
Cheng S; Wang Y; Zhang Z; Lv X; Gao GF; Shao Y; Ma L; Li X
Eur J Med Chem; 2016 Oct; 121():232-237. PubMed ID: 27240277
[TBL] [Abstract][Full Text] [Related]
16. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
[TBL] [Abstract][Full Text] [Related]
17. A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life.
Su S; Rasquinha G; Du L; Wang Q; Xu W; Li W; Lu L; Jiang S
Molecules; 2019 Mar; 24(6):. PubMed ID: 30901967
[TBL] [Abstract][Full Text] [Related]
18. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
19. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
20. Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein.
Gapizov SS; Petrovskaya LE; Shingarova LN; Kryukova EA; Boldyreva EF; Lukashev EP; Yakimov SA; Svirshchevskaya EV; Dolgikh DA; Kirpichnikov MP
Biotechnol Appl Biochem; 2019 Jul; 66(4):617-625. PubMed ID: 31140614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
